CHD1

Across TCGA pan-cancer cohorts, CHD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHD1 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHD1 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and LUAD are the cancer types where CHD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.647	0.848	.002	45	view →
CCRCC	DFS	Median	II,III,IV	0.451	1.000	.008	26	view →
LUAD	DFS	Median	II,III,IV	0.218	0.792	.003	10	view →
HNSC	DFS	Quartile	All	0.551	0.806	.025	7	view →
UCEC	DFS	Tertile	All	0.758	0.908	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHD1–PDAC (DFS)

Open the PDAC breakdown →